Navigation Links
Biomarker predicts effectiveness of brain cancer treatment
Date:7/1/2014

Researchers at the University of California, San Diego School of Medicine have identified a new biomarker that predicts whether glioblastoma the most common form of primary brain cancer will respond to chemotherapy. The findings are published in the July print issue of Oncotarget.

"Every patient diagnosed with glioblastoma is treated with a chemotherapy called temozolomide. About 15 percent of these patients derive long-lasting benefit," said Clark C. Chen, MD, PhD, vice-chairman of Academic Affairs, Division of Neurosurgery, UC San Diego School of Medicine and the study's principal investigator. "We need to identify which patients benefit from temozolomide and which another type of treatment. All therapies involve risk and the possibility of side-effects. Patients should not undergo therapies if there's no likelihood of benefit."

To pinpoint which patients were most likely respond to temozolomide, the researchers studied microRNAs that control the expression of a protein called methyl-guanine-methyl-transferase or MGMT. This protein dampens the cancer-killing effect of temozolomide. Tumors with high levels of MGMT are associated with a poor response to temozolomide therapy.

The scientists systematically tested every microRNA in the human genome to identify those that suppressed MGMT expression, with the expectation that high-levels of these microRNAs in the tumor would predict improved therapeutic response to temozolomide.

"We showed that a signature of the MGMT-regulating microRNAs predicted temozolomide response in a cohort of glioblastoma patients. Validation of these results should lead to diagnostic tools to enable us to determine which patients will benefit most from temozolomide therapy," said Chen.

In the study, the scientists also discovered that injection of the MGMT-regulating microRNAs into glioblastoma cells increased tumor sensitivity to temozolomide treatment.

"These findings establish the foundation for microRNAs-based therapies to increase the efficacy of temozolomide in glioblastoma patients," said lead author, Valya Ramakrishnan, PhD, postdoctoral researcher, UC San Diego School of Medicine.


'/>"/>

Contact: Jackie Carr
jcarr@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert  

Related medicine news :

1. SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples
2. Biomarkers can reveal IBS
3. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
4. Early biomarker for pancreatic cancer identified
5. New biomarker test predicts arthritis at much earlier stage, MU researchers say
6. Biomarker predicts response to cancer treatment
7. Novel biomarkers reveal evidence of radiation exposure
8. GW researchers discover biomarker for advanced bile duct fibrosis and bile duct cancer
9. Using biomarkers to identify and treat schizophrenia
10. US Army: Pre-injury cartilage biomarkers associated with subsequent ACL injuries
11. Biomarkers of behavior, therapeutic targets for adult B-acute lymphoblastic leukemia identified
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biomarker predicts effectiveness of brain cancer treatment
(Date:4/26/2017)... , ... April 26, 2017 , ... ... in Hackensack, N.J. has been honored by Enterprising Women magazine as one of ... the world’s top women business owners. Winners have demonstrated that they have fast-growth ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more ... CRISPRCas.pioneer.com ) that demonstrates how this advanced plant breeding technology is a more ... with fewer resources. It highlights the business’ principles, research and collaboration efforts in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop ... Mirroring360 Pro . This new addition to the Mirroring360 product family combines device ... business. , Mirroring360 Pro enables educators, business professionals and individuals to stream or ...
(Date:4/25/2017)... ... 25, 2017 , ... A recent report from the Wisconsin ... the 2015-16 school year across Wisconsin’s public schools, charter schools, and private schools ... in student test score performance, the report’s limited analyses fail to provide answers ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... in unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as ... premier society for this important science. , The Teratology Society ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... that it will be participating in the Deutsche Bank ... Hotel in Boston, Massachusetts on ... 11:20 a.m. Eastern Time. A live webcast ... Investor Relations website at http://investor.zimmerbiomet.com .  The webcast ...
(Date:4/20/2017)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage ... unmet medical needs, today announced that it will ... development program, based on its proprietary self-delivering RNAi ... (SID) 76 th Annual Meeting.  The SID ... relevant to skin health and disease through education, ...
Breaking Medicine Technology: